Human Reproduction, Vol. 14, No. 9, 2200-2206,
September 1999
© 1999 European Society of Human Reproduction and Embryology
Gonadotrophin and testosterone suppression by 7
-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men
1 Instituto Chileno de Medicina Reproductiva, Santiago, Chile, 2 Steroid Research Laboratory, Department of Medical Chemistry, Institute of Biomedicine, University of Helsinki, Helsinki, Finland, 3 Center for Reproductive Biology, Edinburgh, UK, 4 The Population Council, Center for Biomedical Research, New York, USA and 5 Väestöliitto, The Family Federation of Finland, Helsinki, Finland
The synthetic androgen 7
-methyl-19-nortestosterone (MENT) is a potent suppressor of gonadotrophin that has several advantages for long term administration to normal or hypoandrogenic men. The aim of this study was to examine MENT serum concentrations following subdermal insertion of MENT acetate (MENT Ac) implants and their effects on gonadotrophins, testosterone, dihydrotestosterone (DHT), sex hormone-binding globulin, prostate specific antigen and insulin-like growth factor-1 serum concentrations in normal men. A total of 45 healthy men were recruited at three clinics. Each subject received one, two or four implants for 28 days. Serum samples were obtained before insertion and on days 8, 15, 22, 29, 36 and 43 after implant insertion. The average daily dose delivered in vivo by one implant was ~500 µg. One, two or four MENT Ac implants produced dose dependent and sustained serum MENT concentrations for the entire duration of treatment of 0.7 ± 0.1, 1.2 ± 0.1 and 2.0 ± 0.1 nmol/l respectively. This treatment induced a dose dependent decrease in gonadotrophin and androgen serum levels. Two and four implants induced maximal suppression that was maintained throughout treatment and was completely reversed after removal of the implants. The mean decreases were 93 ± 1% for testosterone, 80 ± 3% for DHT, 97 ± 1% for luteinizing hormone and 95 ± 1% for follicle stimulating hormone. No serious adverse reactions were reported by the volunteers and no consistent changes in clinical chemistry and haematology were found. These results indicate that MENT Ac implants are an efficient way of MENT administration and confirm the potent gonadotrophin and androgen suppressive effect of this drug.
Key words:
gonadotrophins/implant/male contraception/7-methyl-19-nortestosterone/testosterone
6 To whom correspondence should be addressed at: Instituto Chileno de Medicina Reproductiva, Correo 22, Casilla 96, Santiago, Chile
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. L. White, G. Nguyen, W. N. Charman, G. A. Edwards, W. A. Faassen, and C. J. H. Porter Lymphatic Transport of Methylnortestosterone Undecanoate (MU) and the Bioavailability of Methylnortestosterone Are Highly Sensitive to the Mass of Coadministered Lipid after Oral Administration of MU J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 700 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Page, J. K. Amory, and W. J. Bremner Advances in Male Contraception Endocr. Rev., June 1, 2008; 29(4): 465 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Walton, N. Kumar, D. T. Baird, H. Ludlow, and R. A. Anderson 7{alpha}-Methyl-19-Nortestosterone (MENT) vs Testosterone in Combination With Etonogestrel Implants for Spermatogenic Suppression in Healthy Men J Androl, September 1, 2007; 28(5): 679 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iranmanesh and J. D. Veldhuis Combined Inhibition of Types I and II 5 {alpha}-Reductase Selectively Augments the Basal (Nonpulsatile) Mode of Testosterone Secretion in Young Men J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4232 - 4237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-Y. Lui, Y. H. Cheng, D. D Mruk, C. H. Cheng, M. Y. Mo, W. M Lee, and C Y. Cheng {alpha}2-Macroglobulin expression in the liver in response to inflammation is mediated by the testis J. Endocrinol., June 1, 2005; 185(3): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. von Eckardstein, G. Noe, V. Brache, E. Nieschlag, H. Croxatto, F. Alvarez, A. Moo-Young, I. Sivin, N. Kumar, M. Small, et al. A Clinical Trial of 7{alpha}-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5232 - 5239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Turner, A. J. Conway, M. Jimenez, P. Y. Liu, E. Forbes, R. I. McLachlan, and D. J. Handelsman Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4659 - 4667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Anderson, A. M. Wallace, N. Sattar, N. Kumar, and K. Sundaram Evidence for Tissue Selectivity of the Synthetic Androgen 7{alpha}-Methyl-19-Nortestosterone in Hypogonadal Men J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2784 - 2793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Anderson and D. T. Baird Male Contraception Endocr. Rev., December 1, 2002; 23(6): 735 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Anderson, D. Kinniburgh, and D. T. Baird Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wang and R. S. Swerdloff Should the Nonaromatizable Androgen Dihydrotestosterone Be Considered as an Alternative to Testosterone in the Treatment of the Andropause? J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1462 - 1466. [Full Text] [PDF]
|
|
|
|
 |
|
 The European Recombinant Human Chorionic Gonadotro Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG Hum. Reprod., July 1, 2000; 15(7): 1446 - 1451. [Abstract] [Full Text] [PDF]
|
|